HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/1/E80    most recent 00188.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Raju, B. Articles by Cryer, P. E. Search for Related Content PubMed PubMed Citation Articles by Raju, B. Articles by Cryer, P. E.

Mechanism, temporal patterns, and magnitudes of the metabolic responses to the K_ATP channel agonist diazoxide

Division of Endocrinology, Metabolism, and Lipid Research, The General Clinical Research Center and the Diabetes Research and Training Center, Washington University School of Medicine, St. Louis, Missouri

Submitted 30 April 2004 ; accepted in final form 30 August 2004

To assess the mechanism, temporal patterns, and magnitudes of the metabolic responses to the ATP-dependent potassium channel agonist diazoxide, neuroendocrine and metabolic responses to intravenous diazoxide (saline, 1.0 and 2.0 mg/kg) and oral diazoxide (placebo, 4.0 and 6.0 mg/kg) were assessed in healthy young adults. Intravenous diazoxide produced rapid, but transient, decrements (P = 0.0023) in plasma insulin (e.g., nadirs of 2.8 ± 0.5 and 1.8 ± 0.3 µU/ml compared with 7.0 ± 1.0 µU/ml after saline at 4.0–7.5 min) and C-peptide (P = 0.0228) associated with dose-related increments in plasma glucose (P = 0.0044) and serum nonesterified fatty acids (P < 0.0001). After oral diazoxide, plasma insulin appeared to decline, as did C-peptide, again associated with dose-related increments in plasma glucose (P < 0.0001) and serum nonesterified fatty acids (P = 0.0141). Plasma glucagon, as well as cortisol and growth hormone, was not altered. Plasma epinephrine increased (P = 0.0215) slightly only after intravenous diazoxide. There were dose-related increments in plasma norepinephrine (P = 0.0038 and P = 0.0005, respectively), undoubtedly reflecting a compensatory sympathetic neural response to vasodilation produced by diazoxide, but these would not raise plasma glucose or serum nonesterified fatty acid levels. Thus selective suppression of insulin secretion, without stimulation of glucagon secretion, raised plasma glucose and serum nonesterified fatty acid concentrations. These findings define the temporal patterns and magnitudes of the metabolic responses to diazoxide and underscore the primacy of regulated insulin secretion in the physiological regulation of postabsorptive carbohydrate and lipid metabolism.

glucose; insulin; glucagon; epinephrine; norepinephrine; adenosine 5'-triphosphate-dependent potassium channel

This article has been cited by other articles:

				H. Yamazaki, W. Philbrick, K. C. Zawalich, and W. S. Zawalich Acute and chronic effects of glucose and carbachol on insulin secretion and phospholipase C activation: studies with diazoxide and atropine Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E26 - E33. [Abstract] [Full Text] [PDF]

				B. Raju and P. E. Cryer Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E181 - E186. [Abstract] [Full Text] [PDF]

				B. Raju and P. E. Cryer Loss of the Decrement in Intraislet Insulin Plausibly Explains Loss of the Glucagon Response to Hypoglycemia in Insulin-Deficient Diabetes: Documentation of the Intraislet Insulin Hypothesis in Humans Diabetes, March 1, 2005; 54(3): 757 - 764. [Abstract] [Full Text] [PDF]